Interleukin-2 (IL-2) immunotherapy.
Various forms of immunotherapy have been employed for the treatment of cancer patients during the past 5 years, with recombinant interleukin-2 (IL-2) having been widely used in these treatment regimes. The progress of IL-2 immunotherapy is discussed.
Macey
M G
MG
Department of Haematology, London Hospital, England, UK.
Johnston
D H
DH
D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins